Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering

Belite Bio (BLTE) entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary Shares and warrants to purchase 230,770 ADSs, at a purchase price of $65 per ADS and accompanying warrant, pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing of the offering is expected to occur on or about August 8, 2025, subject to the satisfaction of customary closing conditions. The offering was to a single large existing institutional shareholder. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the offering.